Free Trial
NYSE:MTNB

Matinas Biopharma 11/8/2023 Earnings Report

Matinas Biopharma logo
$0.62 -0.02 (-2.47%)
As of 01:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Matinas Biopharma EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Matinas Biopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Matinas Biopharma Earnings Headlines

Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

View Matinas Biopharma Profile

More Earnings Resources from MarketBeat